Positive Airway Pressure Use Tied to Lower Cardiovascular Events
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 17, 2024 -- Positive airway pressure (PAP) utilization is associated with lower all-cause mortality and major adverse cardiovascular event (MACE) incidence in older adults with obstructive sleep apnea (OSA), according to a study published online Sept. 11 in JAMA Network Open.
Diego R. Mazzotti, Ph.D., from the University of Kansas Medical Center in Kansas City, and colleagues sought to determine whether PAP initiation and utilization are associated with lower mortality and incidence of MACE among older U.S. adults with OSA. The analysis included 888,835 Medicare beneficiaries with two or more distinct OSA claims identified from multistate, statewide, multiyear Medicare fee-for-service claims data (2011 to 2020) with follow-up until death or censoring through 2020.
The researchers found that during a median follow-up of 3.1 years, those with evidence of PAP initiation (32.6 percent) had significantly lower all-cause mortality (hazard ratio, 0.53) and MACE incidence risk (hazard ratio, 0.90). There was a progressive association between higher quartiles of annual PAP claims and lower mortality and MACE incidence risk.
"These results might inform future trials assessing the importance of obstructive sleep apnea therapies toward minimizing cardiovascular risk and mortality in older adults," the authors write.
One author disclosed being a cofounder of Hypnoscure.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-18 06:00
Read more
- Globally, Suicide Risk Increased on Certain Days of the Week, Holidays
- Trends in Obesity Treatment Show Surge in GLP-1 RAs, Drop in Surgeries
- Antiviral Treatment Underutilized for Children, Teens With Flu
- Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
- Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
- Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions